Combined treatment with RT plus immunotherapy caused a robust response in pre-clinical studies, with potential PD-L1 inhibition and dendritic cells activation, supporting CD8+ cytotoxic T lymphocytes and mobilizing tumor-specific immunity. Here, CD8A is linked to neoplasm.